Exciting Updates from Trevi Therapeutics
Trevi Therapeutics, Inc. (NASDAQ: TRVI) has exciting news to share regarding their investigational therapy nalbuphine ER, aimed at addressing chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Professor Philip Molyneaux will present key findings from the Phase 2b CORAL trial, showcasing the efficacy and safety results of nalbuphine ER during the upcoming CHEST 2025 Annual Meeting.
Key Presentations Scheduled
The CHEST 2025 Annual Meeting, scheduled to occur from October 19 to 22, will serve as a significant platform for dissemination of crucial information. Not only will Professor Molyneaux present the oral findings, but Associate Professor Imran Satia is also set to present a poster detailing patient-reported outcomes from the Phase 2a RIVER trial, focusing on treatment for refractory chronic cough (RCC).
Overview of the CORAL Trial
The Phase 2b CORAL trial investigated nalbuphine ER's dosage efficacy, examining three different dose levels: 27 mg, 54 mg, and 108 mg, all administered twice daily. This trial was structured as a randomized, double-blind, placebo-controlled study involving 165 participants with chronic cough due to IPF. The primary focus was on measuring the relative change in nighttime cough frequency, utilizing objective monitoring to ensure accurate data.
Trial Logistics
During the trial, participants underwent an initial two-week period to titrate to the target dose, followed by four weeks of consistent dosing. The results aim to clarify nalbuphine ER's effectiveness in reducing cough frequency, contributing valuable insights to the ongoing research surrounding chronic cough management.
Insights from the RIVER Trial
The Phase 2a RIVER trial is another key study that will be showcased at the meeting. This trial focused on patient-reported outcomes and evaluated nalbuphine ER's impact on those suffering from RCC, a condition defined as a persistent cough lasting more than eight weeks despite treatment for any underlying conditions.
Understanding Refractory Chronic Cough
RCC affects an estimated 2-3 million individuals in the U.S., with symptoms that can significantly impact daily life. The RIVER trial will provide necessary insights into how nalbuphine ER can alleviate suffering, targeting the unique challenges presented by this debilitating cough condition.
The Importance of Research
Chronic cough remains a largely neglected area in medical research, especially among patients with IPF and other forms of interstitial lung diseases (ILD). According to recent estimates, approximately 150,000 people in the U.S. live with IPF, and about two-thirds experience uncontrolled coughing that severely affects their quality of life.
This research highlights the urgency of developing effective therapies. Chronic cough may subject patients to frequent hospitalizations, increased morbidity, and a decline in overall health quality due to persistent discomfort and complications from extended coughing.
About Haduvio
Trevi Therapeutics has branded nalbuphine ER as Haduvio, a potential treatment that operates on both central and peripheral cough reflexes as a kappa agonist and mu antagonist (KAMA). This dual-action ensures a more comprehensive approach to manage chronic cough. Currently, Haduvio is the only investigational therapy showing a significant reduction in cough frequency for patients studied to date, representing a groundbreaking shift in treatment potential.
Future Prospects for Chronic Cough Treatment
As Trevi Therapeutics looks ahead, the company is committed to exploring every possibility with Haduvio to establish its efficacy and safety fully. With no FDA-approved therapies currently available for conditions like IPC or RCC, the stakes for this research could not be higher.
Frequently Asked Questions
1. What is the significance of the CHEST 2025 meeting for Trevi Therapeutics?
The CHEST 2025 meeting serves as a vital platform for presenting significant advancements related to Trevi Therapeutics' ongoing research into chronic cough treatments.
2. What are the primary results expected from the CORAL trial presentation?
The presentation aims to share findings that demonstrate nalbuphine ER's efficacy and safety in reducing chronic cough frequency in patients with IPF.
3. How does the RIVER trial contribute to understanding RCC?
The RIVER trial provides critical insights into patient-reported outcomes, helping to evaluate how nalbuphine ER can relieve chronic cough symptoms in patients suffering from RCC.
4. Why is chronic cough in IPF patients considered a high unmet need?
Chronic cough in patients with IPF often has no effective treatments currently approved, leading to significant distress and impaired quality of life.
5. What potential impact does Haduvio have on chronic cough management?
Haduvio is positioned to be a transformative treatment option, specifically targeting the underlying cough mechanisms with a dual-action approach, addressing a critical medical gap.
